THE ONCOGENIC ROLE OF THE SUPER ELONGATION COMPLEX IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS

被引：0
|
作者：
Dahl, Nathan A. [1 ,2 ]
Venkataraman, Sujatha [1 ,2 ]
Balakrishnan, Ilango [1 ]
Madhavan, Krishna [1 ,2 ]
Fosmire, Susan [1 ]
Vibhakar, Rajeev [1 ,2 ]
机构：
[1] Univ Colorado, Sch Med, Dept Pediat, Pediat Neurooncol Program, Denver, CO USA
[2] Morgan Adams Fdn, Pediat Brain Tumor Res Program, Denver, CO USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
DIPG-10
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [1] SUPER ELONGATION COMPLEX-MEDIATED TRANSCRIPTIONAL DEPENDENCY IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
    Dahl, Nathan
    Venkataraman, Sujatha
    Balakrishnan, Ilango
    Madhavan, Krishna
    Fosmire, Susan
    Wang, Dong
    Vibhakar, Rajeev
    NEURO-ONCOLOGY, 2018, 20 : 212 - 212
  • [2] Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant
    Dufour, Charlotte
    Perbet, Romain
    Leblond, Pierre
    Vasseur, Romain
    Stechly, Laurence
    Pierache, Adeline
    Reyns, Nicolas
    Touzet, Gustavo
    Le Rhun, Emilie
    Vinchon, Matthieu
    Maurage, Claude-Alain
    Escande, Fabienne
    Renaud, Florence
    BRAIN PATHOLOGY, 2020, 30 (01) : 179 - 190
  • [3] Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location
    Guidara, Souhir
    Seyve, Antoine
    Poncet, Delphine
    Leonce, Camille
    Bringuier, Pierre-Paul
    McLeer, Anne
    Sturm, Dominik
    Cartalat, Stephanie
    Picart, Thiebaud
    Ferrari, Anthony
    Hench, Juergen
    Frank, Stephan
    Meyronet, David
    Ducray, Francois
    Barritault, Marc
    JOURNAL OF NEURO-ONCOLOGY, 2024, 169 (02) : 391 - 398
  • [4] MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
    Abe, Hideaki
    Natsumeda, Manabu
    Okada, Masayasu
    Watanabe, Jun
    Tsukamoto, Yoshihiro
    Kanemaru, Yu
    Yoshimura, Junichi
    Oishi, Makoto
    Hashizume, Rintaro
    Kakita, Akiyoshi
    Fujii, Yukihiko
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [5] Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
    Huy Gia Vuong
    Ngo, Tam N. M.
    Hieu Trong Le
    Jea, Andrew
    Hrachova, Maya
    Battiste, James
    McNall-Knapp, Rene
    Dunn, Ian F.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Antibody-drug conjugates for H3K27M-mutant diffuse midline gliomas: prospects and challenges
    Rechberger, Julian S.
    Power, A. Erica
    Millesi, Elena
    Daniels, David J.
    THERAPEUTIC DELIVERY, 2021, 12 (08)
  • [7] CHARACTERISTICS OF ADULT DIFFUSE H3K27M-MUTANT GLIOMAS AT RECURRENCE
    Hodroj, K.
    Meyronet, D.
    Barritault, M.
    Bourg, V.
    Cohen-Moyal, E.
    Cartalat, S.
    Ameli, R.
    Berhouma, M.
    Honnorat, J.
    Ducray, F.
    NEURO-ONCOLOGY, 2019, 21 : 11 - 12
  • [8] Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas
    Lu, Victor M.
    Daniels, David J.
    HISTONE MUTATIONS AND CANCER, 2021, 1283 : 73 - 84
  • [9] Defining the role of purine metabolism in radiation resistance in H3K27M-mutant diffuse midline glioma
    Peterson, Erik R.
    Sajjakulnukit, Peter
    Scott, Andrew
    Heaslip, Caleb
    Lyssiotis, Costas
    Castro, Maria G.
    Wahl, Daniel R.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] CLINICAL CHARACTERIZATION OF H3K27M-MUTANT GLIOMAS
    Takezaki, Tatsuya
    Kuroda, Jun-ichiro
    Shinojima, Naoki
    Kai, Keitaro
    Yamamoto, Takahiro
    Fujimoto, Kenji
    Inoue, Hirotaka
    Sueyoshi, Hiroyuki
    Matsuzaki, Keisuke
    Takeshima, Yuki
    Matsuura, Jin
    Mukasa, Akitake
    NEURO-ONCOLOGY, 2024, 26
12345